News
Iveric Bio receives new therapy designation for avacincaptad pegol
Iveric Bio (Iveric) has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation status for avacincaptad pegol (ACP).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Iveric Bio (Iveric) has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation status for avacincaptad pegol (ACP).